1. Introduction: The Evolution of Veterinary Fluoroquinolones

In the critical field of veterinary infectious disease management, the development of potent, broad-spectrum antimicrobial agents is essential for maintaining animal health and ensuring the safety of the global food supply chain. Marbofloxacin (CAS 115550-35-1) represents a pinnacle of third-generation fluoroquinolone development. Developed exclusively for veterinary use, it offers a unique combination of rapid bactericidal activity, high tissue penetration, and a favorable safety profile. Unlike earlier quinolones, Marbofloxacin was engineered to address the specific pharmacokinetic requirements of both companion animals and food-producing livestock, making it a versatile tool for veterinarians worldwide.

2. Chemical Structure and Physicochemical Properties

Marbofloxacin is chemically designated as 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid. Its molecular formula is 

C17H19FN4O4C17​H19​FN4​O4​

, with a molecular weight of 362.36 g/mol .

• Structural Characteristics: The presence of a fluorine atom at the C-9 position significantly enhances its antimicrobial potency against Gram-negative pathogens. The benzoxazine ring system contributes to its metabolic stability and unique pharmacokinetic profile compared to other fluoroquinolones like Enrofloxacin or Ciprofloxacin.

• Solubility and Stability: Marbofloxacin is a pale yellow crystalline powder. It is slightly soluble in water and ethanol but highly stable under standard storage conditions. For B2B procurement, the stability of the API (Active Pharmaceutical Ingredient) is a vital factor, as it ensures a long shelf-life for the final manufactured dosage forms, whether they be oral tablets or injectable solutions.

3. Mechanism of Action: The Precision of DNA Gyrase Inhibition

Marbofloxacin is a potent bactericidal agent that targets the core reproductive machinery of the bacterial cell. Its mechanism of action is concentration-dependent and highly specific:

• DNA Gyrase (Topoisomerase II) Inhibition: In Gram-negative bacteria, Marbofloxacin binds to and inhibits DNA gyrase, the enzyme responsible for introducing negative supercoils into the DNA strand. This inhibition prevents DNA replication and transcription, leading to rapid bacterial death.

• Topoisomerase IV Inhibition: In Gram-positive bacteria, its primary target is often topoisomerase IV, which is responsible for the decatenation (separation) of interlinked daughter chromosomes after replication.

• Dual-Targeting Synergism: By targeting these two vital enzymes, Marbofloxacin minimizes the likelihood of spontaneous bacterial resistance, as the pathogen would often require mutations in both enzymes simultaneously to survive the treatment.

• The Post-Antibiotic Effect (PAE): Marbofloxacin exhibits a significant PAE, meaning bacterial growth continues to be suppressed even after the concentration of the drug at the site of infection falls below the Minimum Inhibitory Concentration (MIC).

4. Pharmacokinetic Profile: Superior Absorption and Distribution

One of the primary reasons for Marbofloxacin’s dominance in the B2B veterinary market is its exceptional pharmacokinetic (PK) behavior across multiple species:

• Bioavailability: Following oral or parenteral administration, Marbofloxacin is absorbed rapidly. In most species, its bioavailability is close to 100%, ensuring that the dosage administered is effectively utilized by the animal's body.

• Tissue Penetration: Marbofloxacin is weakly protein-bound (usually less than 30%), which allows a large fraction of the drug to distribute freely into tissues. It achieves concentrations in the lungs, skin, liver, kidneys, and even the prostate that are significantly higher than those found in the plasma.

• Accumulation in Phagocytes: Marbofloxacin is actively taken up by macrophages and neutrophils. These immune cells then transport the antibiotic directly to the site of infection (chemotaxis), creating a "Trojan Horse" effect that delivers high concentrations of the drug exactly where it is needed most.

• Elimination: It is primarily excreted through both the urine and feces in its active form. This dual route of elimination makes it an excellent choice for treating urinary tract infections (UTIs) as well as systemic infections.

5. Clinical Applications: Targeted Species and Pathogens

Marbofloxacin is utilized in several high-value segments of veterinary medicine:

• Cattle (Bovine): It is a "first-line" treatment for Bovine Respiratory Disease (BRD) associated with Mannheimia hemolytica, Pasteurella multocida, and Histophilus somni. It is also highly effective in treating acute mastitis caused by E. coli.

• Swine (Porcine): Used to manage Postpartum Dysgalactia Syndrome (PDS, formerly known as MMA syndrome) and various respiratory tract infections.

• Dogs and Cats: In companion animal medicine, Marbofloxacin is the standard of care for deep pyoderma, complex UTIs, and upper respiratory tract infections. Its once-daily dosing regimen significantly improves owner compliance.

6. Industrial Manufacturing and Global Quality Standards

For pharmaceutical manufacturers and B2B distributors, the quality of Marbofloxacin API is governed by strict international standards (EP/USP/BP):

• Purity Requirements: Standard technical specifications require an assay of 98.5% to 101.5% on a dried basis.

• Impurity Control: Strict limits are placed on related substances (such as the decarboxylated analog) and residual solvents (such as N,N-Dimethylformamide or Ethanol used in the crystallization process).

• Particle Size Management: Depending on whether the API is intended for the production of oral tablets or sterile injectables, the particle size distribution (PSD) must be carefully controlled to ensure uniform dissolution and syringeability.

• GMP Compliance: Sourcing must be conducted from facilities that hold current Good Manufacturing Practice (GMP) certifications, ensuring that every batch is produced with full traceability and rigorous quality audits.

7. Safety, Toxicology, and MRLs (Maximum Residue Limits)

Regulatory compliance regarding food safety is a critical aspect of Marbofloxacin trade.

• MRLs in Food-Producing Animals: The European Medicines Agency (EMA) and other global bodies have established clear MRLs for Marbofloxacin in bovine and porcine muscle, fat, liver, and kidney, as well as in bovine milk.

• Withdrawal Periods: Withdrawal times are relatively short due to the drug’s efficient elimination, often ranging from 2 to 6 days for meat and 36 to 72 hours for milk, depending on the dose and route of administration.

• Contraindications: Marbofloxacin should be used with caution in young, rapidly growing animals (especially large-breed puppies) due to the potential risk of articular cartilage damage, a characteristic common to the fluoroquinolone class.

8. Market Sourcing and Strategic Procurement Trends

The global market for Marbofloxacin is expanding as it replaces older, less effective antibiotics and as veterinarians seek out more stable and reliable "concentration-dependent" bactericidal agents. For B2B buyers, the focus is shifting toward "Value-Added Sourcing"—not just looking for the lowest price, but seeking suppliers who provide comprehensive regulatory support (DMF/CEP), robust stability data, and specialized particle size grades. As antimicrobial stewardship becomes more prevalent, the demand for high-quality Marbofloxacin as a "critically important" antibiotic remains high.

9. Conclusion

Marbofloxacin stands as a testament to the precision of modern veterinary pharmacology. Its unique mechanism of dual-enzyme targeting, coupled with its superior tissue distribution and high bioavailability, makes it an indispensable asset in both livestock production and companion animal care. By adhering to the highest manufacturing standards and utilizing the latest in chemical synthesis technology, we ensure that our Marbofloxacin provides the efficacy and safety that the global veterinary industry demands.

Contact Us for Bulk Inquiries and Pharmaceutical Support:

Add: Block 14, No.100, Luyun Road, Changsha 410205, Hunan, China.
Email: info@arshinevet.com
WeChat: +8618874001228
WhatsApp: +8615697311407
Tel： 86-731-82294958

Product link：https://arshinevet.com/product-detail/marbofloxacin-ep8